Cetuximab in advanced non-small cell lung cancer
Cetuximab in advanced non-small cell lung cancer
复制标题
DOI：
10.1158/1078-0432.ccr-040015
复制
发表时间：
2004-06-15
影响因子：
11.5
通讯作者：
Govindan, R
中科院分区：
文献类型：
--
作者：
Govindan, R
表皮生长因子受体（EGFR）在非小细胞肺癌（NSCLC）中经常过表达。EGFR活化导致参与细胞增殖、血管生成和细胞凋亡抑制的几种下游细胞内底物的磷酸化。西妥昔单抗C225，爱必妥），一种针对EGFR细胞外结构域中配体结合的单克隆抗体，抑制肿瘤生长，并与化疗和放疗协同。西妥昔单抗与化疗联合用于治疗既往未经治疗的转移性NSCLC。初步报告的答复率从29%到53%不等。在难治性/复发性NSCLC患者中，多西他赛和西妥昔单抗联合治疗的缓解率为28%，高于多西他赛单药治疗的典型缓解率。西妥昔单抗加化疗一般耐受良好。预测西妥昔单抗治疗反应的分子机制目前还不清楚。正在进行研究，以评估西妥昔单抗在转移性NSCLC中的单药活性。
The epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer (NSCLC). EGFR activation results in phosphorylation of several downstream intracellular substrates involved in cell proliferation, angiogenesis, and inhibition of apoptosis. Cetuximab C225, Erbitux), a monoclonal antibody directed against ligand binding in the extracellular domain of EGFR, inhibits tumor growth and is synergistic with chemotherapy and radiation. Cetuximab has been studied in combination with chemotherapy in previously untreated metastatic NSCLC. The response rates in preliminary reports range from 29% to 53%. In patients with refractory/recurrent NSCLC, the combination of docetaxel and cetuximab resulted in a promising response rate of 28%, higher than the typical response rates seen with docetaxel monotherapy in this setting. Addition of cetuximab to chemotherapy is generally well tolerated. Molecular mechanisms predicting response to cetuximab therapy are currently not well understood. Studies are ongoing to assess the single-agent activity of cetuximab in metastatic NSCLC.